ACTINIUM PHARMAC. DL-001(7AY1)

Description: Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

---

Keywords: Solid Tumors Radiation Acute Myeloid Leukemia Antibody Drug Conjugate National Cancer Institute Oncology Therapies Hematopoietic Stem Cell Transplantation Refractory Acute Myeloid Leukemia Camidanlumab Tesirine Bone Marrow Transplant Ac 225

---

Home Page: www.actiniumpharma.com

100 Park Avenue
New York, NY 10017
United States
Phone: 646 677 3870

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)